Bayer

Explore the latest insights on Bayer and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Bayer’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Bayer and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Bayer's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib
CompanyDrug

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GlaxoSmithKline Plc (GSK; NYSE: GSK) announced the first global data for risvutatug rezetecan (Ris‑Rez, HS‑20093), its investigational B7‑H3‑targeted antibody‑drug conjugate (ADC), in patients with relapsed extensive‑stage small cell lung cancer…

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas

Policy / Regulatory

China’s NHC Expands Rare Disease List, Includes 21 Cancer Types

Company

Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms

CompanyDrug

Bayer Subsidiary’s Parkinson’s Treatment Bemdaneprocel Shows Promise in Phase I

CompanyDrug

Bayer Funds Landmark Trials for Kerendia in Heart Failure Treatment Expansion

CompanyDeals

Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies

CompanyDeals

Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement

CompanyDrug

Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept

Show More